51
|
Jang WY, Kim W, Kang DO, Park Y, Park EJ, Na JO, Choi CU, Rha SW, Park CG, Seo HS, Park S, Kim EJ. P4339Reference values for cardiorespiratory fitness in healthy Koreans: compared to western nations and nomogram. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Cardiorespiratory Fitness (CRF), defined as the integrated ability to properly oxygenate skeletal muscles during physical activity, is associated with a high risk of cardiovascular disease and all-cause mortality. The reference range for CRF may differ among nations, with Asians under-represented in previous data.
Purpose
In this study, we sought to establish reference values of CRF for Asians using a recent Korean cohort.
Methods
We analyzed 2646 healthy Korean adults recently enrolled in the Korea Institute of Sports Science Fitness Standards (KISS FitS) project with estimated maximal oxygen uptake (VO2max) values during treadmill test. Patients with cardiovascular or renal disease, systemic infection, pregnant women and those with orthopedic injuries unable to measure physical fitness were excluded. Age-specific mean VO2max values were compared with those from recent American, Norwegian, Danish cohorts and old Korean data.
Results
Age-specific reference values for healthy Korean adults in this cohort were as shown (Table). We were able to draw a nomogram to predict exercise capacity for a given age and MET value (Figure). When compared to other countries, less CRF reduction by aging was seen in Asians than in other Westerners. When compared to old Korean data from the 1980s, values were similar after adjustment for difference in methods, except for those under 30 years old which were decreased.
Exercise capacity of healthy Korean Men Women Age VO2max (ml/kg/min) N P-value for trend Age VO2max (ml/kg/min) N P-value for trend 19–29 42.3±6.3± 209 <0.01 19–29 34.3±4.3± 110 <0.01 30–39 42.0±5.0± 170 39–39 32.2±4.5± 211 40–49 41.4±5.6± 238 40–49 30.8±4.6± 284 50–59 38.0±5.7± 274 50–59 28.3±4.6± 367 60–69 32.4±6.2± 134 60–69 26.0±5.7± 336 70–79 27.2±5.6± 83 70–79 23.9±4.4± 195 >80 24.1±4.0± 11 >80 21.0±3.7± 24 Total 38.6±7.4± 1119 Total 28.5±5.8 1527 Data are presented as mean ± standard deviation. VO2max, maximal oxygen uptake; N, number.
Nomogram of exercise capacity in Koreans
Conclusions
While there was no significant change in CRF over time in the same ethnic group, there was a clear inter-ethnic difference. CRF should be assessed according to ethnic or national standards, and it is necessary to establish a reference for each nation or ethnicity with periodic updates.
Acknowledgement/Funding
National Sports Promotion Fund of the Korea Sports Promotion Foundation in 2015
Collapse
|
52
|
Kang DO, Kim CK, Park Y, Jang WY, Kim W, Choi JY, Choi CU, Na JO. P5744Sleep-disordered breathing assessed by holter-monitoring is associated to worsened one-year clinical outcomes in ischemic stroke patients: a cardiopulmonary coupling analysis. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Sleep-disorder breathing (SDB) using polysomnography is closely associated to poor functional and clinical outcomes in ischemic stroke patients. The cardiopulmonary coupling analysis using Holter-monitoring (CPC-Holter analysis) is an emerging feasible modality to investigate SDB.
Purpose
We investigated the association between SDB defined by CPC-Holter analysis and one-year clinical outcome in patients with acute ischemic stroke.
Methods
Total 666 patients with acute ischemic stroke who underwent Holter-monitoring were enrolled. The CPC-Holter analysis was conducted and SDB was defined as the presence of narrow-band (NB) coupling during sleep time. Primary outcome was recurrent ischemic stroke, and secondary outcome was major adverse cerebrovascular event (MACE), a composite of recurrent ischemic stroke, transient ischemic attack, and all-cause mortality within one year since discharge.
Result
The NB coupling was present in 205 (30.8%) of 666 patients with mean age of 64.1±12.8 years. The NB group showed significantly higher incidence of both recurrent ischemic stroke (8.3% vs. 1.4%, p<0.001) and MACE (14.9% vs. 3.0%, p<0.001) within one-year. In multivariate analysis, presence of NB coupling remained as an independent predictor of both recurrent ischemic stroke and MACE (HR: 4.81; 95% CI: 1.73–13.4; p=0.003; and HR 4.17; 95% CI: 1.74–10.0; p<0.001, respectively). The results were consistent after propensity-score matched analysis with 164 patient pairs (C-statistics=0.757).
One-year clinical outcomes Overall population (n=666) PSM population (n=328) no NB (=461) NB (n=205) Log-rank p-value OR (95% CI) no NB (n=164) NB (n=164) Log-rank p-value OR (95% CI) Recurrent ischemic stroke 6 (1.4) 14 (8.3) <0.001 5.73 (2.20–14.9) 3 (2.0) 11 (8.1) 0.026 3.85 (1.07–13.8) Transient ischemic attack 3 (0.7) 3 (1.7) 0.275 2 (1.3) 3 (2.1) 0.633 Hemorrhagic stroke 0 (0.0) 2 (1.2) 0.027 0 (0.0) 2 (1.5) 0.148 Total death 3 (0.7) 9 (4.8) 0.001 2 (1.3) 3 (1.9) 0.641 MACEs 12 (3.0) 25 (14.9) <0.001 4.63 (2.06–10.4) 7 (5.2) 17 (13.1) 0.030 2.95 (1.06–8.21) Data are expressed as n (%). CI = confidence interval; MACE = major adverse cardiovascular event; NB = narrow-band; OR = odds ratio.
One-year clinical outcomes
Conclusion
SDB assessed by CPC-Holter analysis at early phase of ischemic stroke is a powerful prognostic marker for predicting one-year adverse clinical outcomes. The CPC analysis using Holter-monitoring is a useful modality and could be easily applied to predict clinical outcomes in acute ischemic stroke patients.
Collapse
|
53
|
Chae H, Kim J, Kim W, Lee JS, Song S, Lee M, Chung H, Song J, Ahn JH. PD-L1 expression as a potential therapeutic target and prognostic biomarker in well-differentiated and dedifferentiated liposarcoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz283.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
54
|
Kim W, La Y, Choi Y. EP.107Transthyretin amyloidosis with variant Ile93Val mutation. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
55
|
Pahk K, Joung C, Song HY, Kim S, Kim W. P723A novel CD147 inhibitor SP-8356 attenuates plaque progression and stabilizes vulnerable plaque in ApoE-deficient mice. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Aim
Plaque vulnerability is the crucial pathophysiological feature in atherosclerosis-related cardiovascular event such as myocardial infarction and stroke. CD147 has been suggested to play key roles in plaque vulnerability through interacting with cyclophilin A (CypA) and resultant activation of matrix metalloproteinase-9 (MMP-9). Here we report that the novel synthetic CD147 inhibitor SP-8356 ((1S,5R)-4-(3,4-dihydroxy-5-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one) inhibits CD147/MMP-9 pathways and reduces plaque progression and stabilizes plaque vulnerability.
Methods
Advanced atherosclerotic plaque was induced in apolipoprotein E-deficient (ApoE KO) mice by partial ligation of the right carotid artery coupled with an atherogenic diet. SP-8356 (50 mg/kg) was orally given daily for 3 weeks. Histomolecular analysis was carried out on harvested carotid arteries.
Results
Surface plasmon resonance assay showed the specific binding of SP-8356 with CD147. SP-8356 inhibited CypA-CD147 interaction and MMP-9 activation. In ApoE KO mice model, SP-8356 inhibited plaque formation, reduced the number of macrophages, increased the number of vascular smooth muscle cells, increased the fibrous cap thickness, and increased the collagen type I contents in fibrous cap. SP-8356 also reduced the apoptotic cells in the plaque lesion.
Conclusions
Owing to its improvement of plaque stability and inhibitory effect on plaque development, SP-8356 could be a potential therapeutic drug candidate for atherosclerosis and related clinical manifestations.
Collapse
|
56
|
Jang WY, Kang DO, Park Y, Kim W, Park EJ, Na JO, Choi CU, Rha SW, Park CG, Seo HS, Kim EJ. P2501Validation of FRIEND and ACSM equations for cardiorespiratory fitness: comparison to direct measurement in male CAD patients. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Cardiorespiratory fitness (CRF) is associated with a high risk of cardiovascular disease and all-cause mortality. The regression equation of American College of Sports Medicine (ACSM) was a preferred method for estimating maximal oxygen consumption (VO2max). It is well-known that CRF is overestimated in ACSM equation. Recently, Kokkinos reported more precise equation from the Fitness Registry and the Importance of Exercise National Database (FRIEND). Both equations were made from western healthy people.
Purpose
In this study, we compared VO2max estimated by ACSM and FRIEND equations to VO2max directly measured in male coronary artery disease (CAD) patients.
Methods
We analyzed 103 male CAD patients who underwent percutaneous coronary intervention and who participated in cardiac rehabilitation between June 2015 and December 2018. VO2max was directly measured by the gas exchange analysis during treadmill test with modified Bruce protocol. Exclusive criteria were pulmonary disease, chronic kidney disease on hemodialysis, malignancy, peripheral artery disease, insufficient cardiopulmonary exercise test and orthopedic injuries. Directly measured VO2max were compared to ACSM and FRIEND equations.
Results
Age-specific VO2max values, which were directly measured from male CAD patients, were shown in Table. Smaller CRF difference was shown in FRIEND equation than ACSM equation. Compared to the measured value, CRF estimated by ACSM equation was overestimated by 22%, but the one estimated by FRIEND equation had only 2% gap. Figure presents Bland-Altman plots. ACSM equation had the higher bias (5.52ml/kg/min) compared with FRIEND equation (0.200ml/kg/min).
Comparison table of VO2max estimated by ACSM and FRIEND equations with directly measured VO2max in male CAD patients Age Number VO2max (ml/kg/min) Measured ACSM % predicted FRIEND % predicted 30–39 4 29.5 ± (6.6) 35.7 ± (6.1) 122.3 ± (8.5) 29.1 ± (4.3) 100.1 ± (8.7) 40–49 20 29.1 ± (5.1) 35.7 ± (5.4) 123.6 ± (11.1) 29.1 ± (3.8) 101.2 ± (9.5) 50–59 32 25.6 ± (4.3) 31.5 ± (5.1) 123.8 ± (10.1) 26.2 ± (3.6) 103.2 ± (8.5) 60–69 27 26.0 ± (5.1) 31.1 ± (2.6) 120.5 ± (12.6) 25.9 ± (4.0) 100.8 ± (10.5) 70–79 18 21.2 ± (6.0) 26.8 ± (5.4) 123.2 ± (14.8) 22.8 ± (3.9) 105.2 ± (12.0) >80 2 25.0 ± (10.1) 22.8 ± (2.6) 97 ± (28.9) 19.9 ± (1.9) 85.1 ± (27.0) Total 103 25.7 ± (5.6) 31.4 ± (6.0) 122.2 ± (12.4) 26.1 ± (4.3) 102.1 ± (10.4) Data are presented as mean ± (standard deviation).
Bland-Altman plots
Conclusions
FRIEND equation can estimate CRF more accurately than ACSM equation, even in Asian patients with CAD.
Collapse
|
57
|
Kang DO, Park SY, Park Y, Jang WY, Kim W, Choi BG, Na JO, Choi CU, Kim EJ, Rha SW, Park CG, Hong SJ, Seo HS. 4098Reduced skeletal muscle mass is associated to worsened long-term clinical outcomes in patients with coronary artery disease: a quantitative analysis by computed tomography. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Sarcopenia is closely associated to poor clinical outcomes in patients with atherosclerotic cardiovascular disease (ASCVD). However, it is unclear whether the skeletal muscle mass at baseline has quantitative effect on future cardiovascular outcomes.
Purpose
We investigated the quantitative effect of skeletal muscle mass on future cardiovascular outcomes in patients with coronary artery disease (CAD).
Methods
Total 475 patients those who underwent successful percutaneous coronary intervention (PCI) for CAD and performed computed tomography (CT) scan within 30 days of PCI were enrolled. The cross-sectional area of skeletal muscle at the first lumbar vertebra (L1) level was measured. Whole study population was divided into 4 groups according to the sex-specific quartiles of skeletal muscle index (SMI). Primary outcome was all-cause mortality and secondary outcome was major adverse cardiovascular event (MACE) within 3 years of follow-up.
Results
Mean follow-up duration was 4.11±3.02 years and average time period from the date of PCI to CT scan was −3.33±11.72 days. The incidence of 3-year all-cause mortality (23.2% vs. 9.9% vs. 6.6% vs. 4.4%, p<0.001) and MACE (42.9% vs. 24.0% vs. 14.3% vs. 6.2%, p<0.001) was significantly higher in the group of lower quartiles of L1-SMI. In the fully adjusted multivariable analysis, lower quartiles of L1-SMI was an independent predictor of higher risk of all-cause mortality and MACE (lowest vs. highest quartile; OR: 4.90, 95% CI: 1.54 to 15.5, p=0.007; and OR: 12.3, 95% CI: 4.99 to 30.4, p<0.001, respectively).
Results of 3-year clinical outcomes SMI Q1 (n=124) SMI Q2 (n=116) SMI Q3 (n=112) SMI Q4 (n=123) Log-rank p-value All-cause mortality 27 (23.2) 11 (9.9) 7 (6.6) 5 (4.4) <0.001 Non-fatal MI 9 (8.7) 3 (3.0) 2 (2.0) 3 (2.6) 0.038 Repeat revascularization 20 (24.9) 15 (15.2) 7 (7.1) 4 (3.8) <0.001 Total MACEs 47 (42.9) 26 (24.0) 15 (14.3) 7 (6.2) <0.001 Data are expressed as n (%). MACE = major adverse cardiovascular event; MI = myocardial infarction; SMI = skeletal muscle index; Q = quartile.
Impact of reduced skeletal muscle on CAD
Conclusion
Skeletal muscle mass at baseline is a powerful predictor of future adverse clinical outcomes in patients with CAD undergoing successful PCI. Quantitative assessment of skeletal muscle mass at L1 level by CT scan provides prognostic implication for future cardiovascular risk stratification.
Acknowledgement/Funding
National Research Foundation of Korea (NRF-2016R1A2B3013825), Ministry of Future Creation and Science of Korea (2018K000255)
Collapse
|
58
|
Choi CU, Choi JI, Kim W, Jang WY, Kang DO, Park Y, Na JO, Kim EJ, Rha SW, Park CG, Seo HS, Kim JW. P2523Hand grip strength as a predictor of exercise capacity in coronary heart disease. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
A recent study has shown that quadriceps strength can be used to predict the level of exercise capacity in patients with coronary heart disease (CHD). We investigated whether the relationship between muscular strength and exercise capacity is also observed with hand grip strength (HGS). We studied 443 participants (age, 61.8±11.2 y; 77.7% male) who underwent coronary intervention and participated in cardiac rehabilitation between 2015 and 2018. Participants were assessed for grip strength, measured using a Jamar dynamometer. Logistic regression was used to assess the relationship between various clinical measures (HGS, age, sex, etc) with the distance walked on a 6-minute walk test (6MWT) and maximal oxygen uptake (VO2max). HGS was significantly related to distance walked on the 6MWT (r=0.435, p<0.001). It was the only predictor of all exercise capacity categories, and one of the strongest predictors of each exercise capacity category. A HGS of 25.5% of body weight predicted an achievement of a 200 m walk on the 6MWT (positive predictive value = 0.95). However, HGS less than 35.5% of body weight predicted that 500m could not be done in 6 minutes (negative predictive value = 0.97). This trend was also observed in the subgroups in which VO2max was measured. This study demonstrates that HGS is associated with exercise capacity in CHD and can be used to predict the level of exercise capacity. These findings may contribute to setting the recommended level of daily activity as well as the level of cardiac rehabilitation in CHD.
Logistic regression models for different levels of exercise capacity Level of exercise capacity B±S.E p-value Odd ratio 95% CI Distance of 6MWT 200 m Grip strength 0.054±0.014 <0.001 1.056 1.027–1.086 300 m Grip strength 0.042±0.009 <0.001 1.042 1.024–1.062 400 m Grip strength 0.047±0.011 <0.001 1.048 1.026–1.070 500 m Grip strength 0.051±0.016 0.001 1.053 1.021–1.086 VO2max level 4 METs Grip strength 0.054±0.010 <0.001 1.056 1.036–1.076 6 METs Grip strength 0.059±0.011 <0.001 1.061 1.039–1.083 8 METs Grip strength 0.081±0.015 <0.001 1.085 1.053–1.117 10 METs Grip strength 0.113±0.049 0.019 1.12 1.019–3.232 Data are presented as mean ± standard deviation (SD). 6MWT, 6-minute walk test; STEMI, ST-Elevation Myocardial Infarction; SE, standard error; CI, confidence interval; VO2max, Maximal Oxygen uptake; METs, Metabolic equivalents.
Collapse
|
59
|
Kim W. P11.16 The stemness andinvasiveness of glioblastoma tumorspheres were suppressed by combined treatment with2’-hydroxycinnamaldehyde andtemozolomide. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
Glioblastoma (GBM) is the most common and aggressive human primary brain malignancy. The key properties of GBM, stemness and invasiveness, are known to be associated with a highly unfavorable prognosis. Notably, the process of epithelial-mesenchymal transition (EMT) is closely related to the progression of GBM. On the basis of reports that 2′-hydroxycinnamaldehyde (HCA) and its derivative, 2′-benzoyloxycinnamaldehyde (BCA), suppresses EMT in several human cancer cells, we sought to evaluate the therapeutic efficacy of HCA and BCA, alone and in combination with temozolomide (TMZ), on GBM tumorspheres (TSs).
MATERIAL AND METHODS
Two human GBM TSs were treated with HCA, BCA, or TMZ. Therapeutic effects were evaluated by measuring ATP levels, neurosphere formation, 3D-invasion in collagen matrix, and viability. Protein expression profiles after drug treatment were evaluated by western blotting. In vivo anticancer efficacy of drugs was examined in a mouse orthotopic xenograft model.
RESULTS
Combined treatment of GBM TSs with HCA or BCA and TMZ significantly reduced cell viability, stemness, and invasiveness. Expression levels of stemness-, invasiveness-, and mesenchymal transition-associated markers, Zeb1, N-cadherin, and β-catenin, were also substantially decreased by the combined treatment. The combined treatment also reduced tumor growth in a mouse orthotopic xenograft model.
CONCLUSION
Our findings suggest that HCA and BCA, combined with TMZ, are potential therapeutic agents in the treatment of GBM.
Collapse
|
60
|
Yang J, Lee Y, Yim S, Kim J, Lee H, Choi Y, Lee G, Kim W. 052 A Case of CD30+ T-cell Lymphoproliferative Disorder Following Trauma on the Scalp. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
61
|
Kim W, Cho J, Jay Young JR. Platelet Activity Dose Not Associated With Hemoglobin Level In Patients With Hemodialysis. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
62
|
Kim W, Young RJ, Hyun CJ. Bay 60-2770 Attenuates Doxorubicin-Induced Cardiotoxicity By Preventing Mitochondrial Membrane Potential Loss. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
63
|
Kim S, Chae J, Jung L, Lee S, Lee S, Rhee K, Kim W, Ko J, Lee J, Kim Y. Cytochrome Epoxygenase P450 2j Promote Ppar Α -Mediated Autophagy In Ob-/Ob- Rats. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
64
|
Hattawy M, Baltzell NA, Dupré R, Bültmann S, De Vita R, El Alaoui A, El Fassi L, Egiyan H, Girod FX, Guidal M, Hafidi K, Jenkins D, Liuti S, Perrin Y, Stepanyan S, Torayev B, Voutier E, Adhikari S, Angelini G, Ayerbe Gayoso C, Barion L, Battaglieri M, Bedlinskiy I, Biselli AS, Bossù F, Brooks W, Cao F, Carman DS, Celentano A, Chatagnon P, Chetry T, Ciullo G, Clark L, Cole PL, Contalbrigo M, Crede V, D'Angelo A, Dashyan N, De Sanctis E, Defurne M, Deur A, Diehl S, Djalali C, Ehrhart M, Eugenio P, Fegan S, Filippi A, Forest TA, Fradi A, Garçon M, Gavalian G, Gevorgyan N, Gilfoyle GP, Giovanetti KL, Golovatch E, Gothe RW, Griffioen KA, Harrison N, Hauenstein F, Hayward TB, Heddle D, Hicks K, Holtrop M, Ilieva Y, Ireland DG, Isupov EL, Jo HS, Johnston S, Keller D, Khachatryan G, Khachatryan M, Khanal A, Khandaker M, Kim CW, Kim W, Klein FJ, Kubarovsky V, Kuhn SE, Lanza L, L Kabir M, Lenisa P, Livingston K, MacGregor IJD, Marchand D, Markov N, Mayer M, McKinnon B, Meziani ZE, Mineeva T, Mirazita M, Montgomery RA, Munoz Camacho C, Nadel-Turonski P, Niccolai S, Ostrovidov AI, Pappalardo LL, Paremuzyan R, Pasyuk E, Pogorelko O, Poudel J, Prok Y, Protopopescu D, Ripani M, Riser D, Rizzo A, Rosner G, Rossi P, Sabatié F, Salgado C, Schumacher RA, Sharabian YG, Skorodumina I, Sokhan D, Soto O, Sparveris N, Strauch S, Taiuti M, Tan JA, Tyler N, Ungaro M, Voskanyan H, Wang R, Watts DP, Wei X, Weinstein LB, Wood MH, Zachariou N, Zhang J, Zhao ZW. Exploring the Structure of the Bound Proton with Deeply Virtual Compton Scattering. PHYSICAL REVIEW LETTERS 2019; 123:032502. [PMID: 31386486 DOI: 10.1103/physrevlett.123.032502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 03/12/2019] [Indexed: 06/10/2023]
Abstract
In the past two decades, deeply virtual Compton scattering of electrons has been successfully used to advance our knowledge of the partonic structure of the free proton and investigate correlations between the transverse position and the longitudinal momentum of quarks inside the nucleon. Meanwhile, the structure of bound nucleons in nuclei has been studied in inclusive deep-inelastic lepton scattering experiments off nuclear targets, showing a significant difference in longitudinal momentum distribution of quarks inside the bound nucleon, known as the EMC effect. In this Letter, we report the first beam spin asymmetry (BSA) measurement of exclusive deeply virtual Compton scattering off a proton bound in ^{4}He. The data used here were accumulated using a 6 GeV longitudinally polarized electron beam incident on a pressurized ^{4}He gaseous target placed within the CLAS spectrometer in Hall-B at the Thomas Jefferson National Accelerator Facility. The azimuthal angle (ϕ) dependence of the BSA was studied in a wide range of virtual photon and scattered proton kinematics. The Q^{2}, x_{B}, and t dependencies of the BSA on the bound proton are compared with those on the free proton. In the whole kinematical region of our measurements, the BSA on the bound proton is smaller by 20% to 40%, indicating possible medium modification of its partonic structure.
Collapse
|
65
|
Jürgensen C, Mikulik D, Kim W, Ghisalberti L, Bernard G, Friedl M, Carter WC, Fontcuberta I Morral A, Romero-Gomez P. Growth of nanowire arrays from micron-feature templates. NANOTECHNOLOGY 2019; 30:285302. [PMID: 30952155 DOI: 10.1088/1361-6528/ab1699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Here, we present a two-step annealing procedure to imprint nanofeatures on SiO2 starting from metallic microfeatures. The first annealing transforms the microfeatures into gold nanoparticles and the second imprints these nanoparticles into the SiO2 layer with nanometric control. The resulting nanohole arrays show a high ensemble uniformity. As a potential application, the nanohole mask is used as a selective mask for the Ga self-assisted growth of GaAs nanowires (NWs). Thus, for the first time, a successful implementation of nano-self-imprinting that links high-throughput microlithography with bottom-up NW growth is shown. The beneficial hole morphology of the SiO2 mask promotes high Ga droplet contact angles with the silicon substrate and the formation of single droplets in the mask holes. This droplet predeposition configuration enables a high vertical yield of NWs. Thus, this article describes a new protocol to grow NW devices that combines simultaneously nanosized holes and parallel processing.
Collapse
|
66
|
Abbott B, Abbott R, Abbott T, Abraham S, Acernese F, Ackley K, Adams C, Adhikari R, Adya V, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar O, Aiello L, Ain A, Ajith P, Allen G, Allocca A, Aloy M, Altin P, Amato A, Ananyeva A, Anderson S, Anderson W, Angelova S, Antier S, Appert S, Arai K, Araya M, Areeda J, Arène M, Arnaud N, Arun K, Ascenzi S, Ashton G, Aston S, Astone P, Aubin F, Aufmuth P, AultONeal K, Austin C, Avendano V, Avila-Alvarez A, Babak S, Bacon P, Badaracco F, Bader M, Bae S, Baker P, Baldaccini F, Ballardin G, Ballmer S, Banagiri S, Barayoga J, Barclay S, Barish B, Barker D, Barkett K, Barnum S, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Bawaj M, Bayley J, Bazzan M, Bécsy B, Bejger M, Belahcene I, Bell A, Beniwal D, Berger B, Bergmann G, Bernuzzi S, Bero J, Berry C, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bidler J, Bilenko I, Bilgili S, Billingsley G, Birch J, Birney R, Birnholtz O, Biscans S, Biscoveanu S, Bisht A, Bitossi M, Bizouard M, Blackburn J, Blair C, Tasson J, Taylor R, Tenorio R, Thies F, Thomas M, Thomas P, Thondapu S, Thorne K, Thrane E, Tiwari S, Blair D, Tiwari S, Tiwari V, Toland K, Tonelli M, Tornasi Z, Torres-Forné A, Torrie C, Töyrä D, Travasso F, Traylor G, Blair R, Tringali M, Trovato A, Trozzo L, Trudeau R, Tsang K, Tse M, Tso R, Tsukada L, Tsuna D, Tuyenbayev D, Bloemen S, Ueno K, Ugolini D, Unnikrishnan C, Urban A, Usman S, Vahlbruch H, Vajente G, Valdes G, van Bakel N, van Beuzekom M, Bode N, van den Brand J, Van Den Broeck C, Vander-Hyde D, van Heijningen J, van der Schaaf L, van Veggel A, Vardaro M, Varma V, Vass S, Vasúth M, Boer M, Vecchio A, Vedovato G, Veitch J, Veitch P, Venkateswara K, Venugopalan G, Verkindt D, Vetrano F, Viceré A, Viets A, Boetzel Y, Vine D, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Vyatchanin S, Wade A, Wade L, Wade M, Bogaert G, Walet R, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang J, Wang W, Wang Y, Ward R, Bondu F, Warden Z, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein A, Weiss R, Weldon G, Bonilla E, Wellmann F, Wen L, Wessel E, Weßels P, Westhouse J, Wette K, Whelan J, Whiting B, Whittle C, Wilken D, Bonnand R, Williams D, Williamson A, Willis J, Willke B, Wimmer M, Winkler W, Wipf C, Wittel H, Woan G, Woehler J, Booker P, Wofford J, Worden J, Wright J, Wu D, Wysocki D, Xiao L, Yamamoto H, Yancey C, Yang L, Yap M, Boom B, Yazback M, Yeeles D, Yu H, Yu H, Yuen S, Yvert M, Zadrożny A, Zanolin M, Zelenova T, Zendri JP, Booth C, Zevin M, Zhang J, Zhang L, Zhang T, Zhao C, Zhou M, Zhou Z, Zhu X, Zucker M, Zweizig J, Bork R, Pisarski A, Boschi V, Bose S, Bossie K, Bossilkov V, Bosveld J, Bouffanais Y, Bozzi A, Bradaschia C, Brady P, Bramley A, Branchesi M, Brau J, Briant T, Briggs J, Brighenti F, Brillet A, Brinkmann M, Brisson V, Brockill P, Brooks A, Brown D, Brunett S, Buikema A, Bulik T, Bulten H, Buonanno A, Buskulic D, Buy C, Byer R, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callister T, Calloni E, Camp J, Campbell W, Cannon K, Cao H, Cao J, Capocasa E, Carbognani F, Caride S, Carney M, Carullo G, Casanueva Diaz J, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cerdá-Durán P, Cerretani G, Cesarini E, Chaibi O, Chakravarti K, Chamberlin S, Chan M, Chao S, Charlton P, Chase E, Chassande-Mottin E, Chatterjee D, Chaturvedi M, Chatziioannou K, Cheeseboro B, Chen H, Chen X, Chen Y, Cheng HP, Cheong C, Chia H, Chincarini A, Chiummo A, Cho G, Cho H, Cho M, Christensen N, Chu Q, Chua S, Chung K, Chung S, Ciani G, Ciecielag P, Ciobanu A, Ciolfi R, Cipriano F, Cirone A, Clara F, Clark J, Clearwater P, Cleva F, Cocchieri C, Coccia E, Cohadon PF, Cohen D, Colgan R, Colleoni M, Collette C, Collins C, Cominsky L, Constancio M, Conti L, Cooper S, Corban P, Corbitt T, Cordero-Carrión I, Corley K, Cornish N, Corsi A, Cortese S, Costa C, Cotesta R, Coughlin M, Coughlin S, Coulon JP, Countryman S, Couvares P, Covas P, Cowan E, Coward D, Cowart M, Coyne D, Coyne R, Creighton J, Creighton T, Cripe J, Croquette M, Crowder S, Cullen T, Cumming A, Cunningham L, Cuoco E, Dal Canton T, Dálya G, Danilishin S, D’Antonio S, Danzmann K, Dasgupta A, Da Silva Costa CF, Datrier L, Dattilo V, Dave I, Davier M, Davis D, Daw E, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, DeMarchi L, Demos N, Dent T, De Pietri R, Derby J, De Rosa R, De Rossi C, DeSalvo R, de Varona O, Dhurandhar S, Díaz M, Dietrich T, Di Fiore L, Di Giovanni M, Di Girolamo T, Di Lieto A, Ding B, Di Pace S, Di Palma I, Di Renzo F, Dmitriev A, Doctor Z, Donovan F, Dooley K, Doravari S, Dorosh O, Dorrington I, Downes T, Drago M, Driggers J, Du Z, Ducoin JG, Dupej P, Dwyer S, Easter P, Edo T, Edwards M, Effler A, Ehrens P, Eichholz J, Eikenberry S, Eisenmann M, Eisenstein R, Essick R, Estelles H, Estevez D, Etienne Z, Etzel T, Evans M, Evans T, Fafone V, Fair H, Fairhurst S, Fan X, Farinon S, Farr B, Farr W, Fauchon-Jones E, Favata M, Fays M, Fazio M, Fee C, Feicht J, Fejer M, Feng F, Fernandez-Galiana A, Ferrante I, Ferreira E, Ferreira T, Ferrini F, Fidecaro F, Fiori I, Fiorucci D, Fishbach M, Fisher R, Fishner J, Fitz-Axen M, Flaminio R, Fletcher M, Flynn E, Fong H, Font J, Forsyth P, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fritschel P, Frolov V, Fulda P, Fyffe M, Gabbard H, Gadre B, Gaebel S, Gair J, Gammaitoni L, Ganija M, Gaonkar S, Garcia A, García-Quirós C, Garufi F, Gateley B, Gaudio S, Gaur G, Gayathri V, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Germain V, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giacomazzo B, Giaime J, Giardina K, Giazotto A, Gill K, Giordano G, Glover L, Godwin P, Goetz E, Goetz R, Goncharov B, González G, Gonzalez Castro J, Gopakumar A, Gorodetsky M, Gossan S, Gosselin M, Gouaty R, Grado A, Graef C, Granata M, Grant A, Gras S, Grassia P, Gray C, Gray R, Greco G, Green A, Green R, Gretarsson E, Groot P, Grote H, Grunewald S, Gruning P, Guidi G, Gulati H, Guo Y, Gupta A, Gupta M, Gustafson E, Gustafson R, Haegel L, Halim O, Hall B, Hall E, Hamilton E, Hammond G, Haney M, Hanke M, Hanks J, Hanna C, Hannam M, Hannuksela O, Hanson J, Hardwick T, Haris K, Harms J, Harry G, Harry I, Haskell B, Haster CJ, Haughian K, Hayes F, Healy J, Heidmann A, Heintze M, Heitmann H, Hello P, Hemming G, Hendry M, Heng I, Hennig J, Heptonstall A, Hernandez Vivanco F, Heurs M, Hild S, Hinderer T, Hoak D, Hochheim S, Hofman D, Holgado A, Holland N, Holt K, Holz D, Hopkins P, Horst C, Hough J, Hourihane S, Howell E, Hoy C, Hreibi A, Huerta E, Huet D, Hughey B, Hulko M, Husa S, Huttner S, Huynh-Dinh T, Idzkowski B, Iess A, Ingram C, Inta R, Intini G, Irwin B, Isa H, Isac JM, Isi M, Iyer B, Izumi K, Jacqmin T, Jadhav S, Jani K, Janthalur N, Jaranowski P, Jenkins A, Jiang J, Johnson D, Jones A, Jones D, Jones R, Jonker R, Ju L, Junker J, Kalaghatgi C, Kalogera V, Kamai B, Kandhasamy S, Kang G, Kanner J, Kapadia S, Karki S, Karvinen K, Kashyap R, Kasprzack M, Katsanevas S, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Keerthana N, Kéfélian F, Keitel D, Kennedy R, Key J, Khalili F, Khan H, Khan I, Khan S, Khan Z, Khazanov E, Khursheed M, Kijbunchoo N, Kim C, Kim J, Kim K, Kim W, Kim W, Kim YM, Kimball C, King E, King P, Kinley-Hanlon M, Kirchhoff R, Kissel J, Kleybolte L, Klika J, Klimenko S, Knowles T, Koch P, Koehlenbeck S, Koekoek G, Koley S, Kondrashov V, Kontos A, Koper N, Korobko M, Korth W, Kowalska I, Kozak D, Kringel V, Krishnendu N, Królak A, Kuehn G, Kumar A, Kumar P, Kumar R, Kumar S, Kuo L, Kutynia A, Kwang S, Lackey B, Lai K, Lam T, Landry M, Lane B, Lang R, Lange J, Lantz B, Lanza R, Lartaux-Vollard A, Lasky P, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lecoeuche Y, Lee C, Lee H, Lee H, Lee H, Lee J, Lee K, Lehmann J, Lenon A, Leroy N, Letendre N, Levin Y, Leviton J, Li J, Li K, Li T, Li X, Lin F, Linde F, Linker S, Littenberg T, Liu J, Liu X, Lo R, Lockerbie N, London L, Longo A, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough J, Lousto C, Lovelace G, Lower M, Lück H, Lumaca D, Lundgren A, Lynch R, Ma Y, Macas R, Macfoy S, MacInnis M, Macleod D, Macquet A, Magaña-Sandoval F, Magaña Zertuche L, Magee R, Majorana E, Maksimovic I, Malik A, Man N, Mandic V, Mangano V, Mansell G, Manske M, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markakis C, Markosyan A, Markowitz A, Maros E, Marquina A, Marsat S, Martelli F, Martin I, Martin R, Martynov D, Mason K, Massera E, Masserot A, Massinger T, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Matone L, Mavalvala N, Mazumder N, McCann J, McCarthy R, McClelland D, McCormick S, McCuller L, McGuire S, McIver J, McManus D, McRae T, McWilliams S, Meacher D, Meadors G, Mehmet M, Mehta A, Meidam J, Melatos A, Mendell G, Mercer R, Mereni L, Merilh E, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers P, Miao H, Michel C, Middleton H, Mikhailov E, Milano L, Miller A, Miller A, Millhouse M, Mills J, Milovich-Goff M, Minazzoli O, Minenkov Y, Mishkin A, Mishra C, Mistry T, Mitra S, Mitrofanov V, Mitselmakher G, Mittleman R, Mo G, Moffa D, Mogushi K, Mohapatra S, Montani M, Moore C, Moraru D, Moreno G, Morisaki S, Mours B, Mow-Lowry C, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz E, Muratore M, Murray P, Nardecchia I, Naticchioni L, Nayak R, Neilson J, Nelemans G, Nelson T, Nery M, Neunzert A, Ng K, Ng S, Nguyen P, Nichols D, Nissanke S, Nocera F, North C, Nuttall L, Obergaulinger M, Oberling J, O’Brien B, O’Dea G, Ogin G, Oh J, Oh S, Ohme F, Ohta H, Okada M, Oliver M, Oppermann P, Oram RJ, O’Reilly B, Ormiston R, Ortega L, O’Shaughnessy R, Ossokine S, Ottaway D, Overmier H, Owen B, Pace A, Pagano G, Page M, Pai A, Pai S, Palamos J, Palashov O, Palomba C, Pal-Singh A, Pan HW, Pang B, Pang P, Pankow C, Pannarale F, Pant B, Paoletti F, Paoli A, Parida A, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patil M, Patricelli B, Pearlstone B, Pedersen C, Pedraza M, Pedurand R, Pele A, Penn S, Perez C, Perreca A, Pfeiffer H, Phelps M, Phukon K, Piccinni O, Pichot M, Piergiovanni F, Pillant G, Pinard L, Pirello M, Pitkin M, Poggiani R, Pong D, Ponrathnam S, Popolizio P, Porter E, Powell J, Prajapati A, Prasad J, Prasai K, Prasanna R, Pratten G, Prestegard T, Privitera S, Prodi G, Prokhorov L, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Quetschke V, Quinonez P, Quintero E, Quitzow-James R, Raab F, Radkins H, Radulescu N, Raffai P, Raja S, Rajan C, Rajbhandari B, Rakhmanov M, Ramirez K, Ramos-Buades A, Rana J, Rao K, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze D, Ren W, Ricci F, Richardson C, Richardson J, Ricker P, Riles K, Rizzo M, Robertson N, Robie R, Robinet F, Rocchi A, Rolland L, Rollins J, Roma V, Romanelli M, Romano R, Romel C, Romie J, Rose K, Rosińska D, Rosofsky S, Ross M, Rowan S, Rüdiger A, Ruggi P, Rutins G, Ryan K, Sachdev S, Sadecki T, Sakellariadou M, Salconi L, Saleem M, Samajdar A, Sammut L, Sanchez E, Sanchez L, Sanchis-Gual N, Sandberg V, Sanders J, Santiago K, Sarin N, Sassolas B, Sathyaprakash B, Saulson P, Sauter O, Savage R, Schale P, Scheel M, Scheuer J, Schmidt P, Schnabel R, Schofield R, Schönbeck A, Schreiber E, Schulte B, Schutz B, Schwalbe S, Scott J, Scott S, Seidel E, Sellers D, Sengupta A, Sennett N, Sentenac D, Sequino V, Sergeev A, Setyawati Y, Shaddock D, Shaffer T, Shahriar M, Shaner M, Shao L, Sharma P, Shawhan P, Shen H, Shink R, Shoemaker D, Shoemaker D, ShyamSundar S, Siellez K, Sieniawska M, Sigg D, Silva A, Singer L, Singh N, Singhal A, Sintes A, Sitmukhambetov S, Skliris V, Slagmolen B, Slaven-Blair T, Smith J, Smith R, Somala S, Son E, Sorazu B, Sorrentino F, Souradeep T, Sowell E, Spencer A, Srivastava A, Srivastava V, Staats K, Stachie C, Standke M, Steer D, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stevenson S, Stocks D, Stone R, Stops D, Strain K, Stratta G, Strigin S, Strunk A, Sturani R, Stuver A, Sudhir V, Summerscales T, Sun L, Sunil S, Suresh J, Sutton P, Swinkels B, Szczepańczyk M, Tacca M, Tait S, Talbot C, Talukder D, Tanner D, Tápai M, Taracchini A. All-sky search for continuous gravitational waves from isolated neutron stars using Advanced LIGO O2 data. Int J Clin Exp Med 2019. [DOI: 10.1103/physrevd.100.024004] [Citation(s) in RCA: 87] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
67
|
Abbott BP, Abbott R, Abbott TD, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Agarwal B, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allen G, Allocca A, Aloy MA, Altin PA, Amato A, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arène M, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Atallah DV, Aubin F, Aufmuth P, Aulbert C, AultONeal K, Austin C, Avila-Alvarez A, Babak S, Bacon P, Badaracco F, Bader MKM, Bae S, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Banagiri S, Barayoga JC, Barclay SE, Barish BC, Barker D, Barkett K, Barnum S, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Beer C, Bejger M, Belahcene I, Bell AS, Beniwal D, Bensch M, Berger BK, Bergmann G, Bernuzzi S, Bero JJ, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bilenko IA, Bilgili SA, Billingsley G, Billman CR, Birch J, Birney R, Birnholtz O, Biscans S, Biscoveanu S, Bisht A, Bitossi M, Bizouard MA, Blackburn JK, Blackman J, Blair CD, Blair DG, Blair RM, Bloemen S, Bock O, Bode N, Boer M, Boetzel Y, Bogaert G, Bohe A, Bondu F, Bonilla E, Bonnand R, Booker P, Boom BA, Booth CD, Bork R, Boschi V, Bose S, Bossie K, Bossilkov V, Bosveld J, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Bramley A, Branchesi M, Brau JE, Briant T, Brighenti F, Brillet A, Brinkmann M, Brisson V, Brockill P, Brooks AF, Brown DD, Brunett S, Buchanan CC, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Bustillo JC, Callister TA, Calloni E, Camp JB, Canepa M, Canizares P, Cannon KC, Cao H, Cao J, Capano CD, Capocasa E, Carbognani F, Caride S, Carney MF, Carullo G, Diaz JC, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda CB, Cerdá-Durán P, Cerretani G, Cesarini E, Chaibi O, Chamberlin SJ, Chan M, Chao S, Charlton P, Chase E, Chassande-Mottin E, Chatterjee D, Chatziioannou K, Cheeseboro BD, Chen HY, Chen X, Chen Y, Cheng HP, Chia HY, Chincarini A, Chiummo A, Chmiel T, Cho HS, Cho M, Chow JH, Christensen N, Chu Q, Chua AJK, Chua S, Chung KW, Chung S, Ciani G, Ciobanu AA, Ciolfi R, Cipriano F, Cirelli CE, Cirone A, Clara F, Clark JA, Clearwater P, Cleva F, Cocchieri C, Coccia E, Cohadon PF, Cohen D, Colla A, Collette CG, Collins C, Cominsky LR, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corley KR, Cornish N, Corsi A, Cortese S, Costa CA, Cotesta R, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Crowder SG, Cullen TJ, Cumming A, Cunningham L, Cuoco E, Canton TD, Dálya G, Danilishin SL, D'Antonio S, Danzmann K, Dasgupta A, Costa CFDS, Dattilo V, Dave I, Davier M, Davis D, Daw EJ, Day B, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, Demos N, Denker T, Dent T, De Pietri R, Derby J, Dergachev V, De Rosa R, De Rossi C, DeSalvo R, de Varona O, Dhurandhar S, Díaz MC, Dietrich T, Di Fiore L, Di Giovanni M, Di Girolamo T, Di Lieto A, Ding B, Di Pace S, Di Palma I, Di Renzo F, Dmitriev A, Doctor Z, Dolique V, Donovan F, Dooley KL, Doravari S, Dorrington I, Álvarez MD, Downes TP, Drago M, Dreissigacker C, Driggers JC, Du Z, Dupej P, Dwyer SE, Easter PJ, Edo TB, Edwards MC, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry SS, Eisenmann M, Eisenstein RA, Essick RC, Estelles H, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Fafone V, Fair H, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fee C, Fehrmann H, Feicht J, Fejer MM, Feng F, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferrini F, Fidecaro F, Fiori I, Fiorucci D, Fishbach M, Fisher RP, Fishner JM, Fitz-Axen M, Flaminio R, Fletcher M, Fong H, Font JA, Forsyth PWF, Forsyth SS, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fritschel P, Frolov VV, Fulda P, Fyffe M, Gabbard HA, Gadre BU, Gaebel SM, Gair JR, Gammaitoni L, Ganija MR, Gaonkar SG, Garcia A, García-Quirós C, Garufi F, Gateley B, Gaudio S, Gaur G, Gayathri V, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Germain V, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giacomazzo B, Giaime JA, Giardina KD, Giazotto A, Gill K, Giordano G, Glover L, Goetz E, Goetz R, Goncharov B, González G, Castro JMG, Gopakumar A, Gorodetsky ML, Gossan SE, Gosselin M, Gouaty R, Grado A, Graef C, Granata M, Grant A, Gras S, Gray C, Greco G, Green AC, Green R, Gretarsson EM, Groot P, Grote H, Grunewald S, Gruning P, Guidi GM, Gulati HK, Guo X, Gupta A, Gupta MK, Gushwa KE, Gustafson EK, Gustafson R, Halim O, Hall BR, Hall ED, Hamilton EZ, Hamilton HF, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hannuksela OA, Hanson J, Hardwick T, Harms J, Harry GM, Harry IW, Hart MJ, Haster CJ, Haughian K, Healy J, Heidmann A, Heintze MC, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Hennig J, Heptonstall AW, Hernandez FJ, Heurs M, Hild S, Hinderer T, Hoak D, Hochheim S, Hofman D, Holland NA, Holt K, Holz DE, Hopkins P, Horst C, Hough J, Houston EA, Howell EJ, Hreibi A, Huerta EA, Huet D, Hughey B, Hulko M, Husa S, Huttner SH, Huynh-Dinh T, Iess A, Indik N, Ingram C, Inta R, Intini G, Isa HN, Isac JM, Isi M, Iyer BR, Izumi K, Jacqmin T, Jani K, Jaranowski P, Johnson DS, Johnson WW, Jones DI, Jones R, Jonker RJG, Ju L, Junker J, Kalaghatgi CV, Kalogera V, Kamai B, Kandhasamy S, Kang G, Kanner JB, Kapadia SJ, Karki S, Karvinen KS, Kasprzack M, Katolik M, Katsanevas S, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Keerthana NV, Kéfélian F, Keitel D, Kemball AJ, Kennedy R, Key JS, Khalili FY, Khamesra B, Khan H, Khan I, Khan S, Khan Z, Khazanov EA, Kijbunchoo N, Kim C, Kim JC, Kim K, Kim W, Kim WS, Kim YM, King EJ, King PJ, Kinley-Hanlon M, Kirchhoff R, Kissel JS, Kleybolte L, Klimenko S, Knowles TD, Koch P, Koehlenbeck SM, Koley S, Kondrashov V, Kontos A, Korobko M, Korth WZ, Kowalska I, Kozak DB, Krämer C, Kringel V, Krishnan B, Królak A, Kuehn G, Kumar P, Kumar R, Kumar S, Kuo L, Kutynia A, Kwang S, Lackey BD, Lai KH, Landry M, Lang RN, Lange J, Lantz B, Lanza RK, Lartaux-Vollard A, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lee CH, Lee HK, Lee HM, Lee HW, Lee K, Lehmann J, Lenon A, Leonardi M, Leroy N, Letendre N, Levin Y, Li J, Li TGF, Li X, Linker SD, Littenberg TB, Liu J, Liu X, Lo RKL, Lockerbie NA, London LT, Longo A, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lovelace G, Lück H, Lumaca D, Lundgren AP, Lynch R, Ma Y, Macas R, Macfoy S, Machenschalk B, MacInnis M, Macleod DM, Hernandez IM, Magaña-Sandoval F, Zertuche LM, Magee RM, Majorana E, Maksimovic I, Man N, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markakis C, Markosyan AS, Markowitz A, Maros E, Marquina A, Marsat S, Martelli F, Martellini L, Martin IW, Martin RM, Martynov DV, Mason K, Massera E, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Matone L, Mavalvala N, Mazumder N, McCann JJ, McCarthy R, McClelland DE, McCormick S, McCuller L, McGuire SC, McIver J, McManus DJ, McRae T, McWilliams ST, Meacher D, Meadors GD, Mehmet M, Meidam J, Mejuto-Villa E, Melatos A, Mendell G, Mendoza-Gandara D, Mercer RA, Mereni L, Merilh EL, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers PM, Miao H, Michel C, Middleton H, Mikhailov EE, Milano L, Miller AL, Miller A, Miller BB, Miller J, Millhouse M, Mills J, Milovich-Goff MC, Minazzoli O, Minenkov Y, Ming J, Mishra C, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moffa D, Mogushi K, Mohan M, Mohapatra SRP, Montani M, Moore CJ, Moraru D, Moreno G, Morisaki S, Mours B, Mow-Lowry CM, Mueller G, Muir AW, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz EA, Muratore M, Murray PG, Nagar A, Napier K, Nardecchia I, Naticchioni L, Nayak RK, Neilson J, Nelemans G, Nelson TJN, Nery M, Neunzert A, Nevin L, Newport JM, Ng KY, Ng S, Nguyen P, Nguyen TT, Nichols D, Nielsen AB, Nissanke S, Nitz A, Nocera F, Nolting D, North C, Nuttall LK, Obergaulinger M, Oberling J, O'Brien BD, O'Dea GD, Ogin GH, Oh JJ, Oh SH, Ohme F, Ohta H, Okada MA, Oliver M, Oppermann P, Oram RJ, O'Reilly B, Ormiston R, Ortega LF, O'Shaughnessy R, Ossokine S, Ottaway DJ, Overmier H, Owen BJ, Pace AE, Pagano G, Page J, Page MA, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pal-Singh A, Pan H, Pan HW, Pang B, Pang PTH, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Papa MA, Parida A, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patil M, Patricelli B, Pearlstone BL, Pedersen C, Pedraza M, Pedurand R, Pekowsky L, Pele A, Penn S, Perez CJ, Perreca A, Perri LM, Pfeiffer HP, Phelps M, Phukon KS, Piccinni OJ, Pichot M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Pirello M, Pitkin M, Poggiani R, Popolizio P, Porter EK, Possenti L, Post A, Powell J, Prasad J, Pratt JWW, Pratten G, Predoi V, Prestegard T, Principe M, Privitera S, Prodi GA, Prokhorov LG, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Quetschke V, Quintero EA, Quitzow-James R, Raab FJ, Rabeling DS, Radkins H, Raffai P, Raja S, Rajan C, Rajbhandari B, Rakhmanov M, Ramirez KE, Ramos-Buades A, Rana J, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze DH, Ren W, Ricci F, Ricker PM, Riemenschneider GM, Riles K, Rizzo M, Robertson NA, Robie R, Robinet F, Robson T, Rocchi A, Rolland L, Rollins JG, Roma VJ, Romano R, Romel CL, Romie JH, Rosińska D, Ross MP, Rowan S, Rüdiger A, Ruggi P, Rutins G, Ryan K, Sachdev S, Sadecki T, Sakellariadou M, Salconi L, Saleem M, Salemi F, Samajdar A, Sammut L, Sampson LM, Sanchez EJ, Sanchez LE, Sanchis-Gual N, Sandberg V, Sanders JR, Sarin N, Sassolas B, Sathyaprakash BS, Saulson PR, Sauter O, Savage RL, Sawadsky A, Schale P, Scheel M, Scheuer J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schuette D, Schulte BW, Schutz BF, Schwalbe SG, Scott J, Scott SM, Seidel E, Sellers D, Sengupta AS, Sennett N, Sentenac D, Sequino V, Sergeev A, Setyawati Y, Shaddock DA, Shaffer TJ, Shah AA, Shahriar MS, Shaner MB, Shao L, Shapiro B, Shawhan P, Shen H, Shoemaker DH, Shoemaker DM, Siellez K, Siemens X, Sieniawska M, Sigg D, Silva AD, Singer LP, Singh A, Singhal A, Sintes AM, Slagmolen BJJ, Slaven-Blair TJ, Smith B, Smith JR, Smith RJE, Somala S, Son EJ, Sorazu B, Sorrentino F, Souradeep T, Spencer AP, Srivastava AK, Staats K, Steer DA, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Steltner B, Stevenson SP, Stocks D, Stone R, Stops DJ, Strain KA, Stratta G, Strigin SE, Strunk A, Sturani R, Stuver AL, Summerscales TZ, Sun L, Sunil S, Suresh J, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Tait SC, Talbot C, Talukder D, Tamanini N, Tanner DB, Tápai M, Taracchini A, Tasson JD, Taylor JA, Taylor R, Tewari SV, Theeg T, Thies F, Thomas EG, Thomas M, Thomas P, Thorne KA, Thrane E, Tiwari S, Tiwari V, Tokmakov KV, Toland K, Tonelli M, Tornasi Z, Torres-Forné A, Torrie CI, Töyrä D, Travasso F, Traylor G, Trinastic J, Tringali MC, Trozzo L, Tsang KW, Tse M, Tso R, Tsukada L, Tsuna D, Tuyenbayev D, Ueno K, Ugolini D, Urban AL, Usman SA, Vahlbruch H, Vajente G, Valdes G, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, van Heijningen JV, van Veggel AA, Vardaro M, Varma V, Vass S, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Venugopalan G, Verkindt D, Vetrano F, Viceré A, Viets AD, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Vyatchanin SP, Wade AR, Wade LE, Wade M, Walet R, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang JZ, Wang WH, Wang YF, Ward RL, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wellmann F, Wen L, Wessel EK, Weßels P, Westerweck J, Wette K, Whelan JT, Whiting BF, Whittle C, Wilken D, Williams D, Williams RD, Williamson AR, Willis JL, Willke B, Wimmer MH, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Wofford JK, Wong WK, Worden J, Wright JL, Wu DS, Wysocki DM, Xiao S, Yam W, Yamamoto H, Yancey CC, Yang L, Yap MJ, Yazback M, Yu H, Yu H, Yvert M, Zadrożny A, Zanolin M, Zelenova T, Zendri JP, Zevin M, Zhang J, Zhang L, Zhang M, Zhang T, Zhang YH, Zhao C, Zhou M, Zhou Z, Zhu SJ, Zhu XJ, Zimmerman AB, Zucker ME, Zweizig J. Tests of General Relativity with GW170817. PHYSICAL REVIEW LETTERS 2019; 123:011102. [PMID: 31386391 DOI: 10.1103/physrevlett.123.011102] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Revised: 03/21/2019] [Indexed: 06/10/2023]
Abstract
The recent discovery by Advanced LIGO and Advanced Virgo of a gravitational wave signal from a binary neutron star inspiral has enabled tests of general relativity (GR) with this new type of source. This source, for the first time, permits tests of strong-field dynamics of compact binaries in the presence of matter. In this Letter, we place constraints on the dipole radiation and possible deviations from GR in the post-Newtonian coefficients that govern the inspiral regime. Bounds on modified dispersion of gravitational waves are obtained; in combination with information from the observed electromagnetic counterpart we can also constrain effects due to large extra dimensions. Finally, the polarization content of the gravitational wave signal is studied. The results of all tests performed here show good agreement with GR.
Collapse
|
68
|
Yim S, Lee YH, Chae SW, Kim W. Squamoid eccrine ductal carcinoma of the ear helix. Clin Case Rep 2019; 7:1409-1411. [PMID: 31360499 PMCID: PMC6637325 DOI: 10.1002/ccr3.2129] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Revised: 03/09/2019] [Accepted: 03/12/2019] [Indexed: 11/11/2022] Open
Abstract
Chronic cutaneous ulcer on the ear helix of 80-year-old male was diagnosed with squamoid eccrine ductal carcinoma (SEDC). SEDC is characterized by both atypical squamous and ductal differentiation. SEDC frequently appears on sun-exposed areas. It could show local recurrence despite complete resection. These characteristics demand cautious attention to SEDC.
Collapse
|
69
|
Kim C, Kim W, Han Y, Kim J, Chon H. Cancer immunotherapy with STING agonist and PD-1 immune checkpoint inhibitor effectively suppresses peritoneal carcinomatosis of colon cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.130] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
70
|
Bak G, Choi JH, Jang HI, Jang JS, Jeon SH, Joo KK, Ju K, Jung DE, Kim JG, Kim JH, Kim JY, Kim SB, Kim SY, Kim W, Kwon E, Lee DH, Lee HG, Lee YC, Lim IT, Moon DH, Pac MY, Park YS, Rott C, Seo H, Seo JW, Seo SH, Shin CD, Yang JY, Yoo J, Yu I. Fuel-Composition Dependent Reactor Antineutrino Yield at RENO. PHYSICAL REVIEW LETTERS 2019; 122:232501. [PMID: 31298906 DOI: 10.1103/physrevlett.122.232501] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Revised: 05/16/2019] [Indexed: 06/10/2023]
Abstract
We report a fuel-dependent reactor electron antineutrino (ν[over ¯]_{e}) yield using six 2.8 GW_{th} reactors in the Hanbit nuclear power plant complex, Yonggwang, Korea. The analysis uses 850 666 ν[over ¯]_{e} candidate events with a background fraction of 2.0% acquired through inverse beta decay (IBD) interactions in the near detector for 1807.9 live days from August 2011 to February 2018. Based on multiple fuel cycles, we observe a fuel ^{235}U dependent variation of measured IBD yields with a slope of (1.51±0.23)×10^{-43} cm^{2}/fission and measure a total average IBD yield of (5.84±0.13)×10^{-43} cm^{2}/fission. The hypothesis of no fuel-dependent IBD yield is ruled out at 6.6σ. The observed IBD yield variation over ^{235}U isotope fraction does not show significant deviation from the Huber-Mueller (HM) prediction at 1.3 σ. The measured fuel-dependent variation determines IBD yields of (6.15±0.19)×10^{-43} and (4.18±0.26)×10^{-43} cm^{2}/fission for two dominant fuel isotopes ^{235}U and ^{239}Pu, respectively. The measured IBD yield per ^{235}U fission shows the largest deficit relative to the HM prediction. Reevaluation of the ^{235}U IBD yield per fission may mostly solve the reactor antineutrino anomaly (RAA) while ^{239}Pu is not completely ruled out as a possible contributor to the anomaly. We also report a 2.9 σ correlation between the fractional change of the 5 MeV excess and the reactor fuel isotope fraction of ^{235}U.
Collapse
|
71
|
Witzig T, Sokol L, Kim W, Foss F, Jacobsen E, de la Cruz Vincente F, Caballero D, Advani R, Roncero Vidal J, Marin-Niebla A, Rodriguez Izquierdo A, de Ona Navarrete R, Terol M, Domingo-Domenech E, Rodriguez M, Piris M, Bolognese J, Janes M, Burrows F, Kessler L, Mishra V, Curry R, Kurman M, Scholz C, Gualberto A. TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T-CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM A PHASE 2 STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.32_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
72
|
Tam C, Wang M, Simpson D, Opat S, Cull G, Munoz J, Phillips T, Kim W, Atwal S, Wei R, Huang J, Elstrom R, Trotman J. UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB-3111). Hematol Oncol 2019. [DOI: 10.1002/hon.55_2630] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
73
|
Jeong S, Kim S, Hong J, Park Y, Kang H, Koh Y, Lee G, Lee W, Yang D, Do Y, Kim M, Yoo K, Yun W, Yi J, Jo J, Eom H, Kwak J, Shin H, Park B, Lee J, Yi S, Kwon J, Oh S, Kim H, Sohn B, Won J, Hong D, Lee H, Suh C, Kim W. A PROSPECTIVE REGISTRY STUDY OF PEG-G-CSF PROPHYLAXIS FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (CISL 1403). Hematol Oncol 2019. [DOI: 10.1002/hon.122_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
74
|
Kim S, Jo J, Yoon D, Hong J, Do Y, Yea J, Lim S, Shin H, Lee H, Yhim H, Yi J, Choi Y, Kim M, Yang D, Lee W, Kang H, Suh C, Kim W. RANDOMIZED PHASE II STUDY OF CHOP VS. FRACTIONATED ICED IN TRANSPLANT-ELIGIBLE PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T-CELL LYMPHOMA: INTERIM RESULTS OF CISL1504. Hematol Oncol 2019. [DOI: 10.1002/hon.146_2631] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
75
|
Illidge T, Horwitz S, Iyer S, Bartlett N, Kim W, Tilly H, Belada D, Feldman T, Illés Á, Jacobsen E, Hüttmann A, Zinzani P, O'Connor O, Trepicchio W, Miao H, Rao S, Onsum M, Manley T, Advani R. RESPONSE TO A+CHP BY CD30 EXPRESSION IN THE ECHELON-2 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.92_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|